Literature DB >> 10801059

The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase.

D Pelled1, H Shogomori, A H Futerman.   

Abstract

We have recently demonstrated that incubation of cultured rat hippocampal neurons with conduritol beta-epoxide (CBE), an inhibitor of glucocerebrosidase, the enzyme defective in Gaucher disease, results in changes in intracellular morphology and in functional calcium stores. Changes in levels of functional calcium stores are directly related to neuronal cell death. We now show that neurons incubated with either CBE or a non-hydrolysable analogue of GlcCer (glucosylthioceramide), are more sensitive to the toxic effects of high concentrations of glutamate and of a variety of metabolic inhibitors. A linear relationship exists between level of accumulation of GlcCer and the extent of neuronal cell death. The deleterious effects of elevated GlcCer levels can be completely reversed by addition of human glucocerebrosidase (imiglucerase) to the culture medium. Imiglucerase is internalized to lysosomes, where it presumably degrades excess GlcCer. This suggests that the limited success of enzyme replacement therapy in neuronopathic forms of Gaucher disease is not due to lack of efficacy of glucocerebroside in degrading GlcCer in neurons of the central nervous system, and adds impetus to attempts to develop ways to efficiently deliver glucocerebrosidase to the brains of neurologically compromised Gaucher disease patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10801059     DOI: 10.1023/a:1005622001239

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  26 in total

1.  Light microscopic and ultrastructural study on CNS lesions in infantile Gaucher's disease.

Authors:  J Cervos-Navarro; C Zimmer
Journal:  Clin Neuropathol       Date:  1990 Nov-Dec       Impact factor: 1.368

2.  Calcium-containing organelles display unique reactivity to chemical stimulation in cultured hippocampal neurons.

Authors:  E Korkotian; M Segal
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

3.  Glucosidases.

Authors:  G Legler
Journal:  Methods Enzymol       Date:  1977       Impact factor: 1.600

4.  Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure.

Authors:  Y Liu; K Suzuki; J D Reed; A Grinberg; H Westphal; A Hoffmann; T Döring; K Sandhoff; R L Proia
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

5.  Gaucher disease in mice induced by conduritol-B-epoxide: morphologic features.

Authors:  M Adachi; B W Volk
Journal:  Arch Pathol Lab Med       Date:  1977-05       Impact factor: 5.534

6.  In vitro accumulation of glucocerebroside in neuroblastoma cells: a model for study of Gaucher disease pathobiology.

Authors:  E M Prence; P Chaturvedi; D S Newburg
Journal:  J Neurosci Res       Date:  1996-02-01       Impact factor: 4.164

Review 7.  The roles of ceramide in the regulation of neuronal growth and development.

Authors:  A H Futerman
Journal:  Biochemistry (Mosc)       Date:  1998-01       Impact factor: 2.487

8.  Effects of low dietary intake of methionine, choline or proteins on the biotransformation of arsenite in the rabbit.

Authors:  M Vahter; E Marafante
Journal:  Toxicol Lett       Date:  1987-06       Impact factor: 4.372

9.  Opening of ATP-sensitive potassium channels by cromakalim confers tolerance against chemical ischemia in rat neuronal cultures.

Authors:  A Reshef; O Sperling; E Zoref-Shani
Journal:  Neurosci Lett       Date:  1998-07-03       Impact factor: 3.046

10.  The internalization of a short acyl chain analogue of ganglioside GM1 in polarized neurons.

Authors:  A Sofer; G Schwarzmann; A H Futerman
Journal:  J Cell Sci       Date:  1996-08       Impact factor: 5.285

View more
  12 in total

Review 1.  Glycosphingolipidoses: beyond the enzymatic defect.

Authors:  Annick Raas-Rothschild; Irene Pankova-Kholmyansky; Yaacov Kacher; Anthony H Futerman
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 2.  Exploring genetic modifiers of Gaucher disease: The next horizon.

Authors:  Brad A Davidson; Shahzeb Hassan; Eric Joshua Garcia; Nahid Tayebi; Ellen Sidransky
Journal:  Hum Mutat       Date:  2018-09-11       Impact factor: 4.878

3.  Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy.

Authors:  Todd E Fox; Xianlin Han; Samuel Kelly; Alfred H Merrill; Rex E Martin; Robert E Anderson; Thomas W Gardner; Mark Kester
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

4.  Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse.

Authors:  Young Bin Hong; Eun Young Kim; Sung-Chul Jung
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

5.  Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms.

Authors:  Emyr Lloyd-Evans; Dori Pelled; Christian Riebeling; Anthony H Futerman
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

6.  Down-regulation of Bcl-2 in the fetal brain of the Gaucher disease mouse model: a possible role in the neuronal loss.

Authors:  Young Bin Hong; Eun Young Kim; Sung-Chul Jung
Journal:  J Hum Genet       Date:  2004-06-04       Impact factor: 3.172

7.  Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.

Authors:  Azza Abdel Gawad Tantawy; Eman Mounir Sherif; Amira Abdel Moneam Adly; Sahar Hassanine; Amina Hafez Awad
Journal:  J Inherit Metab Dis       Date:  2013-03-19       Impact factor: 4.982

8.  A model of neuronopathic Gaucher disease.

Authors:  P E Campbell; C M Harris; C M Harris; T Sirimanna; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

9.  Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease.

Authors:  Mario A Cabrera-Salazar; Matthew Deriso; Scott D Bercury; Lingyun Li; John T Lydon; William Weber; Nilesh Pande; Mandy A Cromwell; Diane Copeland; John Leonard; Seng H Cheng; Ronald K Scheule
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

Review 10.  New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy.

Authors:  Michael Beck
Journal:  Hum Genet       Date:  2006-11-07       Impact factor: 5.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.